weekending:- 22-11-2019 legal publication date:- …ipo.gov.pk/system/files/191227.pdfmr. iftikhar...
Post on 25-Jun-2020
0 Views
Preview:
TRANSCRIPT
Electronic Publication of Patents Journal
under The Patents (Amendments) Act, 2016
Weekending:- 22-11-2019
Legal Publication Date:- 27-12-2019
Journal Code (191227)
Patents’ journal 27-12-2019
1
NEW APPLICATIONS FOR THE PATENTS
The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents
Ordinance 2000.
18/11/2019
771/2019
Monsanto Technology LLC. U.S.A.
―PLANT REGULATORY ELEMENTS AND
USES THEREOF‖
772/2019
Monsanto Technology LLC. U.S.A.
“PLANT REGULATORY ELEMENTS AND USES THEREOF”
773/2019
Monsanto Technology LLC . U.S.A.
“PLANT REGULATORY ELEMENTS AND USES THEREOF”
774/2019
Monsanto Technology LLC . U.S.A.
“PLANT REGULATORY ELEMENTS AND USES THEREOF”
775/2019
AIC Chile SpA, Chile.
(Priority 16/11/2018 CL)
“Method, reaction chamber and system for the treatment of liquids in continuous flow”
776/2019
Salma Bilal; Hajera Gul,; Anwar-ul-Haq Ali Shah, and Ulrike Krewer. Pakistan.
“Intrinsically conductive polymer nanocomposite with versatile abilities for energy storage”
19/11/2019
777/2019
IFTIKHAR AHMED ZAHOOR. Pakistan.
“SOLAR POWER ELECTRIC & HYBRID CAR KIT (SPECK)”
20/11/2019
778/2019
HELIO DA IGREJA. Brazil.
“THERMOCHEMICAL TREATMENT SYSTEM FOR PLASTIC AND / OR ELASTOMERIC
Patents’ journal 27-12-2019
2
(Priority 04/12/2018 US)
WASTE”
779/2019
Prof. Dr. Shah Khusro and Mr. Iftikhar Alam. Pakistan.
“Methods And System For Real-Time Group Profile Generation and Recommendations On Smart Tv”
780/2019
DOW AGROSCIENCES LLC, U.S.A.
(Priority 15/03/2013 US)
“N-OXIDE OF 4-AMINO-6-(HETEROCYCLIC) PICOLINATE AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATE COMPOUND”
781/2019
DOW AGROSCIENCES LLC, U.S.A.
(Priority 15/03/2013 US)
“AGRICULTURALLY ACCEPTABLE SALT OF 4-AMINO-6-(HETEROCYCLIC) PICOLINATE AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATE COMPOUND”
782/2019
DOW AGROSCIENCES LLC, U.S.A.
(Priority 15/03/2013 US)
“N-OXIDE OF 4-AMINO-6-(HETEROCYCLIC) PICOLINATED AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATE COMPOUND”
783/2019
Mr. Iftikhar Alam and Prof. Dr. Shah Khusro Pakistan.
“METHOD AND SYSTEM FOR CREATING A COMPREHENSIVE E-TUTOR OF A TEXTBOOK WITH MULTIMEDIA CONTENT OF VARYING LEVELS OF DETAILS TO REDUCE TEACHING EFFORT IN ALL INSTRUCTION ENVIRONMENTS”
784/2019
DOW AGROSCIENCES LLC, U.S.A.
(Priority 15/03/2013 US)
“AGRICULTURALLY ACCEPTABLE SALT OF 4-AMINO-6-(HETEROCYCLIC)PICOLINATE AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATE COMPOUND”
785/2019
Mr. Iftikhar Alam; Prof. Dr. Shah Khusro and Mr. Mumtaz khan. Pakistan.
“Methods, System and Design of a Smartphone-Based Social Assistant for Helping Blind Users in Academic Environment”
786/2019
STAUBLI FAVERGES. France.
(Priority 21/11/2018 FR)
“Cooling device for a shedding machine of a weaving machine”
787/2019
Enanta Pharmaceuticals, Inc.
“FUNCTIONALIZED HETEROCYCLES AS
Patents’ journal 27-12-2019
3
U.S.A.
(Priority 21/11/2018 US)
ANTIVIRAL AGENTS”
22/11/2019
788/2019
Dr. Hafiz Muhammad Tahir and Dr. Shaukat Ali Pakistan.
“Serisore”
789/2019
FMC Corporation. U.S.A.
(Priority 26/11/2018 US)
“META-DIAMIDE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS”
790/2019
Novartis AG. Switzerland.
(Priority 27/11/2018 US)
“CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS”
Patents’ journal 27-12-2019
4
APPLICATION ACCEPTED
Notice is hereby given that the person interested in opposing the grant of Patents to any of the
applications referred to below at any time within four months from the date of this Patents’
journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules
18(1) of 2003.
The six figures number shown in the right hand side are those given to applications on
acceptance of the complete specification under which the specification will be printed and
subsequent proceeding taken.
The figures shown within square brackets after the title of inventions indicate their classification
index at acceptance.
Typed copies of the specification which are to open to public inspection can be supplied by the
Patent Office on payment of the prescribed charges which may be as certained on application to
the office.
683/2011
Enanta Pharmaceuticals, Inc.
U.S.A.
―MACROCYCLIC PROLINE DERIVED HCV
SERINE PROTEASE INHIBITOR‖
A61K38/21.
143350
The present invention discloses a compound of
formula I:
which inhibits serine protease activity,
particularly the activity of hepatitis C virus
(HCV) NS3-NS4A protease. Consequently, the
compound of the present invention interferes with
the life cycle of the hepatitis C virus and is also
Patents’ journal 27-12-2019
5
useful as an antiviral agent. The present invention
further relates to a pharmaceutical composition
comprising the aforementioned compound for
administration to a subject suffering from HCV
infection.
157/2013
Stora Enso Oyj.
Finland.
―DEEP-DRAWN PAPER TRAY, A METHOD
FOR MAKING IT‖
B32B38/12, B65D1/34, B65D1/26 &
B29C51/108.
143351
The invention concerns a deep-drawn paper tray
(4), particularly a shallow tray made of
paperboard or cardboard.The tray comprises a
bottom (4a) and upwardly expanding side walls
around the bottom, the side walls of the tray being
shaped to expand through a plurality of
circumferential steps (4b, 4c, 4d) dimensioned
low enough for obtaining wrinkle-free side walls
for the tray. The outermost step is a flat, wrinkle-
free rim flange (4d), which enables liquid and gas
proof heat-sealing of a lid to form the package.
The apparatus according to the invention may
comprise upper and lower moulding tools (10, 11)
with concentric movable frames (10b, 10c, 10d)
for forming the tray bottom and side wall steps to
paper blanks, and moulding tools (10) may be
mounted onto a rotating turret (9) carrying a paper
blank through working stations arranged along the
turret circumference, to shape the tray bottom and
the side wall steps at the consecutive stations.
Patents’ journal 27-12-2019
6
375/2013
Novartis AG.
Switzerland.
―AN AQUEOUS COMPOSITION
COMPRISING AN ANTI-BAFFR ANTIBODY‖
C07C9/11.
143352
Anti-BAFFR antibodies are formulated as liquid
formulation comprising a high concentration of
the antibody active ingredient for delivery to a
patient without high levels of antibody
aggregation. The aqueous pharmaceutical
composition may include one or more sugars, a
buffering agent, a surfactant, and/or a free amino
acid.
476/2013
GlaxoSmithKline Intellectual
Property (No.2) Limited.
United Kingdom.
―The Non-Steroidal Compound: (R)-1 -(1 -
(méthylsulfonyl) propan-2-yl)-4-
(trifluoromethyl)-1H-indole-5-carbonitrile, and
it's use as a modulator of the androgen receptor‖
C07D401/06 & A61K31/44.
143353
The present invention relates to a compound, of
the Formula I:
Patents’ journal 27-12-2019
7
wherein:
indicates a single or double bond;
R1 is -CF3, -C≡N, or halo;
R2 is H, C1-3 alkyl, or -CHF2;
R3 is C1-3 alkyl;
R4 is -C(CH3)(CF3)OH, -CH2SCH3, -
CH2S(O)2CH3, -C(O)CH3 or phenyl or pyridinyl,
wherein said phenyl or pyridinyl is optionally
substituted with one or two groups selected from -
C≡N and halo; and
R5 is H or methyl.
This invention relates to non-steroidal compound
that is modulator of androgen receptor, to the
method for the making and use of such
compound. This invention also provides a
pharmaceutical composition comprising a
compound to accelerate wound healing.
94/2014
Eisai R&D Management Co.,
Ltd.
Japan.
―MONOCYCLIC PYRIDINE COMPOUND AS
FGFR INHIBITOR‖
C07D401/14 & A61K 31/45.
143354
The present invention provides a novel compound
having FGFR inhibitory activity and a
pharmaceutical composition containing the same.
Specifically, the present invention provides a
compound represented by the following formula
Patents’ journal 27-12-2019
8
(I):
wherein n represents 0 to 2; A represents an
arylene group or a heteroarylene group; G
represents a single bond, an oxygen atom or —
CH2—; E represents a nitrogen-containing non-
aromatic heterocycle; R1 represents an alkoxy
group, an alkoxy alkoxy group or the like;
R2 represents a hydrogen atom, a halogen atom, a
hydroxyl group, an alkyl group, a hydroxyl alkyl
group, a nitrogen-containing non-aromatic
heterocyclic group or the like; and R3 represents a
hydrogen atom, an alkyl group, an alkoxy group
or the like, with the proviso that when E
represents an azetidine ring and R2 or R
3 is
present on a nitrogen atom on the azetidine ring,
the R2 or R
3 does not represent a hydrogen atom.
305/2015
Novartis AG.
Switzerland.
―NOVEL PYRAZOLO PYRIMIDINE
COMPOUND AND PHARMACEUTICAL
COMPOSITION THEREOF‖
C07D487/04, A61K31/519, A61P37/00,
A61P29/00 &A61P 35/00.
143355
The present invention provides a compound of
formula (I);
Patents’ journal 27-12-2019
9
Wherein variables R1 and R2 are as defined in the
claims of the specification.
The present invention further provides a
pharmaceutical composition comprising a
compound and one or more pharmaceutically
acceptable carriers and therapeutically effective as
a MALT1 (mucosa associated lymphoid tissue
lymphoma translocation protein 1) inhibitor.
523/2016
Eisai R&D Management Co.,
Ltd.
Japan.
―PHARMACEUTICALLY ACCEPTABLE
SALT OF MONOCYCLIC PYRIDINE
DERIVATIVE AS FGFR INHIBITOR‖
C07D401/14 & A61K31/45.
143356
The present invention provides a
pharmaceutically acceptable salt of a compound
having FGFR inhibitory activity and a
pharmaceutical composition containing the same.
Specifically, the present invention provides a
pharmaceutically acceptable salt of a compound
represented by the following formula (I):
wherein n represents 0 to 2; A represents an
arylene group or a heteroarylene group; G
represents a single bond, an oxygen atom or —
CH2—; E represents a nitrogen-containing non-
aromatic heterocycle; R1 represents an alkoxy
group, an alkoxy alkoxy group or the like; R2
represents a hydrogen atom, a halogen atom, a
hydroxyl group, an alkyl group, a hydroxyl alkyl
group, a nitrogen-containing non-aromatic
heterocyclic group or the like; and R3 represents a
hydrogen atom, an alkyl group, an alkoxy group
or the like, with the proviso that when E
Patents’ journal 27-12-2019
10
represents an azetidine ring and R2 or R
3 is
present on a nitrogen atom on the azetidine ring,
the R2 or R
3 does not represent a hydrogen atom.
485/2017
Erber Aktiengesellschaft.
Austria.
―PARTICLE CONTAINING AT LEAST A
VOLATILE SUBSTANCE AND PROCESS
FOR ITS PREPARATION‖
A61K9/50 & A61K8/02.
143357
The invention is directed to a particle containing
at least a volatile substance comprising a core
comprising at least one matrix material and the at
least one volatile substance and at least one
coating layer, whereby a first coating layer is a
non-confluent layer comprising at least a carrier
material, whereby optionally the non-confluent
layer contains at least one hydrophobic substance,
and optionally the particle is surrounded by at
least one confluent layer and / or further non-
confluent layer(s) as well as to a process for
producing the same.
Patents’ journal 27-12-2019
11
515/2017
Mr. Arish Rvaan Malik.
Pakistan.
―Cemented Heating Disc‖
H01L21/02, H05B3/74, H05B3/20, H05B 3/06 &
H05B3/10.
143358
Round shaped cemented heating disc is applied as
an industrial application to heat dies, molds &
platens. It mainly consist of 2 different parts
(Upper part & Lower Base). The Upper part is
made of Stainless sheet metal and the lower base
is a mild steel jacket that has been lathed and
milled to make a groove inside the mild steel for
supporting heating elements inside the groove to
provide even distribution of heat in the die
surface. The hole in the middle of the disc is to
adjust the cemented heating disc on the dies,
molds and platens or clamp it according to the
needs. There are two electric terminals on the
upper stainless sheet which supply current to the
elements in the groove to produce heat.
326/2018
Novartis AG.
Switzerland.
―PHARMACEUTICALLY ACCEPTABLE
SALT OF PYRAZOLO PYRIMIDINE
COMPOUND AND PHARMACEUTICAL
COMPOSITION THEREOF‖
C07D487/04 & C07D471/04.
143359
Patents’ journal 27-12-2019
12
The present invention provides a
pharmaceutically acceptable salt of a compound
of formula (I);
Wherein variables R1 and R2 are as defined in the
claims of the specification. The present invention
further provides a pharmaceutical composition
comprising a pharmaceutically acceptable salt of a
compound and one or more pharmaceutically
acceptable carriers which is therapeutically
effective as a MALT1 (mucosa associated
lymphoid tissue lymphoma translocation protein
1) inhibitor.
649/2019
Enanta Pharmaceuticals, Inc.
U.S.A.
―MACROCYCLIC PROLINE DERIVED HCV
SERINE PROTEASE INHIBITOR‖
A61K38/21.
143360
The present invention discloses a compound of
formula I:
which inhibits serine protease activity,
particularly the activity of hepatitis C virus
(HCV) NS3-NS4A protease. Consequently, the
compound of the present invention interferes with
Patents’ journal 27-12-2019
13
the life cycle of the hepatitis C virus and is also
useful as an antiviral agent. The present invention
further relates to a pharmaceutical composition
comprising the aforementioned compound for
administration to a subject suffering from HCV
infection.
Patents’ journal 27-12-2019
14
NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS
Design
No. Title & Class Applicant
19/11/2019
20172 TANK (Class-03) Hamza Mehmood, Trading as Plastic
World (Pvt) Limited
20173 Divider (Class-03) Sayyed Engineers Limited
20174 Compass (Class-03) Sayyed Engineers Limited
20/11/2019
20175 (ROUND JAR) (Class-03) Mr. OZAIR UR REHMAN S/o NAIM UR
REHMAN KHAN
20176 Bottle (Class-03) Muhammad Ali as M.A.A International,
20177 PERFUME BOTTLE (Class-04) Anoop Kumar
20178 PERFUME BOTTLE (Class-04) Anoop Kumar
20179 PERFUME BOTTLE (Class-04) Anoop Kumar
20180 PERFUME BOTTLE (Class-04) Anoop Kumar
20181 PERFUME BOTTLE (Class-04) Anoop Kumar
20182 PERFUME BOTTLE (Class-04) Anoop Kumar
20183 PERFUME BOTTLE (Class-04) Anoop Kumar
20184 PERFUME BOTTLE (Class-04) Anoop Kumar
20185 PERFUME BOTTLE (Class-04) Anoop Kumar
20186 PERFUME BOTTLE (Class-04) Anoop Kumar
20187 MANHOLE COVER (Class-03) Anoop Kumar
21/11/2019
20188 Pouch for Drinking Water (Class-05) Ali Asghar, M&H Product
Patents’ journal 27-12-2019
15
22/11/2019
20189 Sharpener (Class-3)
Muhammad Ali Sultan S/O Sultan Salahuddin 2) Sohail Mumtaz S/O
Mumtazuddin 3) Suleman Saleem S/O Saleemuddin
20190 Eraser (Class-03)
Muhammad Ali Sultan S/O Sultan Salahuddin 2) Sohail Mumtaz S/O
Mumtazuddin 3) Suleman Saleem S/O Saleemuddin
20191 BOX (Class-03) Nawaz Ahmed S/o Irshad Muhammad,
20192 PERFUME BOTTLE (Class-04) Anoop Kumar
Patents’ journal 27-12-2019
16
REGISTRATION OF DESIGNS
The following designs have been registered.
S. No. Design
No. Title & Class Applicant
21-11-2019
1. 19721 Foldable (Class-12) Hafiz Muhammad Saleem Iqbal
2. 19849 RUBBER TRANSMISSION BELT
(Class 3) SHAHRYAR
3. 19973 PEN (Class-03) Ameer Ullah Khan
4. 20002 MP3 AUDIO PLAYER (Class 1) MUHAMMAD SARWAR
5. 20129 Carpet (Class-08) Ch. Mubasher Hussain (Chief
Executive), Nayyer Industries (Pvt.) Ltd.,
6. 20012 Carpet (Class-08) Ch. Mubasher Hussain (Chief
Executive), Nayyer Industries (Pvt.) Ltd.,
7. 20016 Pencil Box (Class-03) INDUS PENCIL INDUSTRIES (PVT)
LIMITED
8. 20130 Carpet (Class-08) Ch. Mubasher Hussain (Chief
Executive), Nayyer Industries (Pvt.) Ltd.,
9. 20131 Carpet (Class-08) Ch. Mubasher Hussain (Chief
Executive), Nayyer Industries (Pvt.) Ltd.,
10. 20132 Carpet (Class-08) Ch. Mubasher Hussain (Chief
Executive), Nayyer Industries (Pvt.) Ltd.,
11. 20133 Carpet (Class-08) Ch. Mubasher Hussain (Chief
Executive), Nayyer Industries (Pvt.) Ltd.,
-sd-
(Dr. Muhammad Fayyaz Ahmad)
Controller of Patents
& Registrar of Designs
Ph: 99230591
top related